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Background: Androgen deprivation (AD) is generally used as a first-line palliative treatment in prostate cancer
(PCa) patients with rising prostate-specific antigen (PSA) after primary therapy. To acquire an accurate detection of
tumour viability following AD with positron emission tomography (PET), an androgen-independent uptake of tracers
would be advantageous. Several metabolic PET tracers are employed for detecting recurrent PCa. We evaluated the
effect of AD on the uptake of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), [11C]choline and [11C]acetate in vivo.
Methods: An [18F]FDG, [11C]choline and [11C]acetate baseline micro(μ)PET/μ computed tomography (CT) scan was
subsequently performed in xenografts of androgen-sensitive (LAPC-4) and androgen-independent (22Rv1) tumours in
nude mice. An untreated control group was compared to a surgical castration group, i.e. androgen-deprived group.
μPET/μCT imaging with the above-mentioned tracers was repeated 5 days after the start of treatment. The percentage
change of SUVmax and SUVmeanTH in the tumours was calculated.
Results: AD did not significantly affect the uptake of [18F]FDG and [11C]choline in LAPC-4 tumours as compared with
the uptake of both tracers in untreated tumours. In control 22Rv1 tumours, [11C]choline and [18F]FDG uptake increased
over time. However, compared with the uptake in control tumours, AD significantly decreased the uptake of [11C]
choline and tended to decrease [18F]FDG uptake. [11C]acetate uptake remained unaffected by AD in both PCa
xenograft models.
Conclusions: [18F]FDG and especially [11C]choline PET, which is currently used for the detection of recurrent PCa, could
miss or underestimate the presence of local recurrent PCa following AD therapy. [11C]acetate uptake occurs
independently of androgens and thus may be more favourable for detecting tumour viability during or following AD.
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Prostate cancer (PCa) is the second most common
cancer affecting approximately 17% of the male popula-
tion and is worldwide becoming a considerable health
issue with an increasing incidence during the last decade
[1]. Primary therapy including prostatectomy or radio-
therapy intends to cure this disease. Nevertheless, local
and/or distal recurrences arise within 10 years in 20% to
40% of all patients. Because PCa development and pro-
liferation is initially driven by androgens, androgen
deprivation (AD) is the first-line therapy for recurrent
PCa. However, over time, biochemical failure occurs and
castration-resistant PCa (CRPC) develops which requires
a change of treatment. Therefore, an accurate detection
of tumour viability of recurrent PCa following AD is
warranted.
Using conventional imaging techniques such as ultra-
sound, computed tomography (CT) or magnetic reson-
ance imaging, an accurate definition of a treatment
response in relapsing patients is not always evident.
Therefore, molecular imaging using positron emission
tomography (PET) could be advantageous in this setting
since biological changes usually precede morphological
alterations and an early tumour-specific response could
be defined. At present, 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG), which visualises the increased glucose
demand of tumours, is generally used in oncologic PET
imaging. However, [18F]FDG PET is less valuable in PCa
due to the slow growth rate of this tumour entity. The
renal excretion of the tracer and an equally increased
tracer uptake in benign prostatic hyperplasia or prostatitis
further hampers the detection of the primary tumour
[2-4]. Some reports describe the detection of metastases
by means of [18F]FDG PET [5]. However, to better visual-
ise local PCa recurrences, radiolabelled choline and [11C]
acetate have been evaluated. Choline PET imaging reflects
the membrane duplication of proliferating cells, whereas
[11C]acetate PET visualises the enhanced lipid synthesis
[6] in cancer cells. In a comparative study, both tracers
performed similarly [7]. Also, both tracers demonstrate a
more favourable excretion pattern compared to that of
[18F]FDG [8,9]. A correlation of choline uptake with cellu-
lar proliferation rate was not found [10]. Nevertheless,
radiolabelled choline is currently applied in most centres
for the detection of PCa recurrences and is being investi-
gated for assessing therapeutic response.
The development, proliferation and maintenance of
normal and malignant prostate cells are controlled by
androgens, which activate androgen receptor (AR)
signalling. To this end, patients relapsing after primary
therapy are generally treated with AD in order to inhibit
PCa proliferation and to induce apoptosis of tumour cells.
Although AR signalling controls the expression of many
target genes, it is not fully elucidated so far whether theuptake of metabolic PET tracers such as [18F]FDG, [11C]
choline and [11C]acetate is substantially hampered by
interfering with this molecular signalling pathway during
AD. In the clinical setting, anti-hormonal therapy has
been shown to reduce the [18F]FDG and [11C]choline
PET signal in PCa [11-13]. Besides therapeutic effects
such as suppression of tumour growth and decreased
tumour viability, this observation could in part result
from a therapy-induced inhibition of cellular uptake
mechanisms. Also, AR signalling is ongoing in CRPC
and seems to be of importance for disease maintenance.
Therefore, androgen may influence gene expression pat-
terns while tumour proliferation remains independent of
AD treatment.
Thus, following the start of AD treatment at advanced
stages of PCa, metabolic imaging may be affected, which
could result in a disturbed detection of early treatment
response and a false negative PET scan. For this purpose,
we evaluated the short-term effect of AD on the uptake of
[18F]FDG, [11C]choline and [11C]acetate in a hormone-
naive and a CRPC animal model.
Methods
Cell lines
The human-derived PCa cell lines LAPC-4 (androgen-
sensitive) [14] and 22Rv1 (androgen-independent yet
androgen-responsive) [15-17] were cultured at 37°C in a
humidified incubator with 5% CO2/95% air atmosphere.
The wild-type AR-expressing LAPC-4 cell line was
kindly provided by Prof. Karen Knudson (the Kimmel
Cancer Center, Thomas Jefferson University, Philadelphia,
PA, USA). LAPC-4 cells were grown in Iscove’s modified
Dulbecco’s medium (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% foetal bovine serum
(FBS) (Invitrogen, Life Technologies, Carlsbad, CA, USA),
2 mM L-glutamine (Invitrogen), and 100 μg/ml strepto-
mycin and 100 U/ml penicillin (Invitrogen). The 22Rv1
cell line is a preclinical model mimicking the progression
towards CRPC. The AR population of 22Rv1 is heteroge-
neous consisting of a constitutive active truncated AR
(ARΔLBD), and a mutated - substitution of tyrosine for
histidine (H875Y) in the LBD and/or an in-frame exon 3
duplication (E3DM) in the DNA-binding domain - AR.
The 22Rv1 cell line (American Type Culture Collection,
Manassas, VA, USA) was cultured in RPMI 1640 medium
(Invitrogen) supplemented with 10% FBS and 3 mM
L-glutamine.
Animal model
Seven-week-old male athymic nu/nu mice were obtained
from Janvier (Le Genest Saint Isle, France). The animals
were housed in individually ventilated cages and kept
under a 12 h light–dark cycle. Animal experiments were
performed according to the strict guidelines for care and
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committee of the KU Leuven.
PCa xenografted tumours were grown subcutaneously
in both shoulders of the animal. LAPC-4 xenografted mice
were obtained approximately 6 weeks after the injection of
5 × 106 cells with matrigel (1:1) (BD Biosciences, San Jose,
CA, USA) in a final volume of 100 μl. 22Rv1 cells were
concentrated to 2 × 106 cells per 100 μl, giving tumours
after about 1 month. Follow-up of developing tumours
was accomplished by calliper measurement, and tumour
volumes (mm3) were calculated with the equation l × w ×
h × (π/6) (length (l), width (w) and height (h) represent
the three orthogonal dimensions of the tumour in
millimetres). A tumour size of at least 150 mm3 was re-
quested for inclusion into the micro(μ)PET imaging study.
Study design
For all mice, an [18F]FDG, [11C]choline and [11C]acetate
baseline μPET scan was performed subsequently. The
mice were divided in two groups: an untreated control
group (n = 6 for LAPC-4 and 22Rv1) and a surgical
castration group for AD (n = 7 for LAPC-4, n = 6 for
22Rv1). Control animals received a sham operation.
[18F]FDG, [11C]choline and [11C]acetate μPET imaging
was repeated 5 days after surgery (follow-up). The
experimental design is illustrated in Figure 1. Preceding
μPET scanning, tumour size (mm3) was measured using
a calliper. Prostate-specific antigen (PSA) plasma levels
were determined after baseline but before the start of
treatment and after follow-up μPET imaging. At the end
of the experiment, the weight of the seminal vesicles and
prostate was determined and normalised to the body
weight of the animal to control for efficient AD, and
histological examination (H&E staining) was performed
on isolated tumour tissues.
μPET/μCT acquisition
Approximately 4 to 6 weeks after subcutaneous cell
inoculation, baseline scanning of the animals was done
(Focus 220 microPET, Concorde-CTI/Siemens, Knoxville,
TN, USA). Mice were first anaesthetised with 1% to 2%
isoflurane, and body weight was determined. Tracer injec-
tion was then done via the tail vein before mice were fixed
in a designed holder that is compatible for the μPET and
μCT scanner and aids the co-registration of both images.Figure 1 Schematic illustration of the study design.The average dose (mean ± SD) of [18F]FDG, [11C]choline
and [11C]acetate at the start of μPET imaging was 8.28 ±
0.60, 9.19 ± 1.28 and 4.33 ± 0.53 MBq, respectively. The
holder was placed, and tumours were positioned in the
field of view of the μPET scanner. Further, a transmission
scan was acquired to correct for attenuation. A 10-min
static μPET scan of [18F]FDG was obtained 1 h post injec-
tion for all animals. In advance, mice were fasted for at
least 6 h and received an intramuscular injection of 1 mg
furosemide (Lasix, Sanofi-Aventis, Diegem, Belgium) at
the same time as the tracer injection in order to reduce
reconstruction artefacts. μPET imaging was performed
using the optimal acquisition times for [11C]choline and
[11C]acetate available from the literature. The optimal
scanning interval was determined as the point where, in a
dynamic PET acquisition, a steady state was reached. The
first two animals of each xenograft model were evaluated,
and literature data were confirmed [10,18]. Uptake of
[11C]choline in the LAPC-4 and 22Rv1 tumour model was
determined for 10 min starting 5 min after injection of the
tracer. [11C]acetate tumour uptake was determined in
these animal models during a 10-min static scan 30 min
post injection (Figure 2).
Directly after μPET imaging, animals were positioned
in the μCT scanner while still fixed to the designed
holder. A small-animal CT scanner (SkyScan 1076,
Skyscan, Kontich, Belgium) for three-dimensional (3D)
tumour localisation and delineation was used. During
μCT scanning, the detector and X-ray source (X-ray
energy 50 kV) rotated around a fixed bed in a step and
shoot mode which allowed the animal to be kept in the
same horizontal position as in the μPET scanning device.
Imaging fusion and quantitative analysis
List mode data of μPET images were converted into 3D
sinograms, followed by 3D filtered back projection
(FBP). μCT images were reconstructed using a standard
protocol and software provided by the manufacturer.
The μPET and μCT data sets were imported into PMOD
and co-registered using fiducial markers placed on the
designed animal holder. Volumes of interest (VOIs) were
drawn around the tumour to obtain the maximal
standardised uptake value (SUVmax). In addition to
SUVmax, the mean standardised uptake value with thresh-
old (SUVmeanTH with TH = Percentage of SUVmax) was
Figure 2 Schematic illustration of the μPET imaging protocol of
(a) [18F]FDG, (b) [11C]choline and (c) [11C]acetate.
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genic effect on tracer uptake. The threshold was set at
65% for [18F]FDG and 20% for [11C]choline and [11C]ace-
tate. Threshold values were chosen empirically in order to
approximate a VOI including only viable tumour tissue.
To eliminate the dependency on the injected dose and
animal weight, SUV values were calculated using the
following formula: SUV = Measured radioactivity concen-
tration in the tumour (Bq/g) × Body weight (g)/Injected
dose (Bq). The changed SUV in each tumour was calcu-
lated as the percentage of the baseline scan on day 0:Figure 3 Percentage changed SUVmax and SUVmeanTH values of tracer
mice. Percentage changed SUV values of (a) [18F]FDG, (b) [11C]choline and
xenografted mice. Data are presented as mean ± SEM. Significant differencPercentage change = (SUV(x) − SUV(0)/SUV(0) × 100%),
where SUV(x) is the tracer uptake on day x.
Statistical analysis
Statistical analysis was performed using Graphpad Prism
(San Diego, CA, USA). For each experimental group,
data are expressed as the mean percentage changed
SUV ± standard error of the mean (SEM). To evaluate
the effect of AD on the uptake of the tracers in
androgen-sensitive and androgen-independent PCa, data
were analysed with one-way ANOVA and Bonferroni
post-hoc testing. For evaluating the effect of AD on
prostate and seminal vesicle weight and PSA secretion,
mean values were compared using the unpaired
Student’s t test; p values ≤ 0.05 indicate significant dif-
ferences between the mean values of abovementioned
parameters in the control and castration group.
Results and discussion
Results
Effect of AD on metabolic PET imaging in hormone-naive PCa
Castration-induced AD did not have a significant effect
on metabolic PET imaging as measured by SUVmax in
hormone-naive LAPC-4 xenografts (Figure 3). Looking
into detail, the following results were obtained: in
control animals, [18F]FDG uptake remained stable over
time (3.53 ± 10.12%), whereas a non-significant
increased uptake was observed in tumours of castrateduptake in control and castrated LAPC-4 tumour-xenografted
(c) [11C]acetate in control (n = 6) and castrated (n = 7) LAPC-4 tumour
es between both groups are indicated with p < 0.05.
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SUVmax values were observed in control and AD-treated
animals over time (−12.28 ± 6.25% versus −15.87 ±
3.81%). Similar as for both other tracers, AD did not
significantly affect the uptake of [11C]acetate in control
and treated animals. Moreover, [11C]acetate uptake
remained stable in both experimental groups (3.57 ±
8.48% versus 1.54 ± 8.73%). Identical results regarding
the effect of AD on tracer uptake were obtained with the
SUVmeanTH values (Figure 3). AD did not significantly
decrease the in vivo uptake of [18F]FDG (5.51 ± 9.92%
versus 14.74 ± 9.33%), [11C]choline (17.38 ± 14.43% ver-
sus −12.95 ± 7.26%) and [11C]acetate (−5.98 ± 5.88%
versus 10.59 ± 11.48%). However, compared to the
uptake in control tumours, [11C]choline uptake tended
to decrease following castration.
Effect of AD on metabolic PET imaging in CRPC
AD decreased the uptake of [18F]FDG and [11C]choline in
the androgen-independent yet responsive 22Rv1 xenograft
model (Figure 4a,b). [18F]FDG uptake increased over time
in the control group (30.20 ± 8.33%), whereas trapping of
this tracer remained unchanged upon AD treatment
in vivo (1.63 ± 6.15%). Like [18F]FDG, [11C]choline uptake
increased over time in control tumours (41.51 ± 16.39%).
However, AD significantly reduced the uptake of [11C]
choline in animals following this treatment (−26.07 ±Figure 4 Percentage changed SUVmax and SUVmeanTH values of tracer
Percentage changed SUV values of (a) [18F]FDG, (b) [11C]choline and (c) [11
xenografted mice. Data are presented as mean ± SEM. Significant differenc6.97%) (Figures 4b and 5). In contrast with both these
tracers, [11C]acetate uptake in control tumours remained
stable (−8.92 ± 7.30%) and did not differ from the uptake
in AD-treated animals (−2.97 ± 8.85%) (Figure 4c). Results
of the SUVmeanTH values are in agreement with those of
SUVmax (Figure 4). An inhibiting effect of AD was
observed on the uptake of [18F]FDG and [11C]choline
(35.32 ± 8.72% versus −0.88 ± 6.27% and 44.30 ± 19.01%
versus −26.62 ± 9.06%, respectively), while the in vivo
uptake of [11C]acetate remained unaffected (−14.85 ±
7.71% versus −0.68 ± 9.97%).Tumour growth and histology
Based on calliper measurement, surgical castration did
not significantly change the tumour size of LAPC-4 (p =
0.1941) and 22Rv1 (p = 0.6881) xenografted animals over
time. Morphological differences were not observed in
viable tumour cells of control compared to those of
castrated animals (Figure 6). Also, necrosis occurred
equally in control and AD-treated tumours of each PCa
model. Inflammation was observed in all tumours, yet
this was not increased by AD. In viable tumour tissues,
inflammation was absent or barely present, whereas
inflammatory cells - polynuclear and, to a lesser extent,
mononuclear cells - were observed surrounding or with-
in necrotic areas.uptake in control and castrated 22Rv1 tumour-xenografted mice.
C]acetate in control (n = 6) and castrated (n = 6) 22Rv1 tumour-
es between both groups are indicated with p < 0.05.
Figure 5 μPET/μCT image of [18F]FDG (a), [11C]choline (b) and [11C]acetate (c) uptake in a representative 22Rv1 tumour. SUVmax and
SUVmeanTH were determined in the tumour before and after AD. They demonstrate the inhibition of tracer uptake (stabilised [
18F]FDG uptake and
decreased [11C]choline uptake under AD versus increased uptake in control). AD did not affect the uptake of [11C]acetate. μPET [18F]FDG data are
scaled from 0 to 2 SUV, those of [11C]choline and [11C]acetate from 0 to 1 SUV. T, tumour.
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Over time, AD significantly diminished PSA secretion of
LAPC-4, but not 22Rv1 tumour cells, which indicates
the androgen sensitivity of exclusively the LAPC-4 cells
in vivo (Table 1). Weights of the prostate and seminal
vesicles were reduced in treated animals compared to
those of control animals (Tables 2 and 3) which demon-
strate a successful AD therapy in vivo.
Discussion
The current study investigated the short-term impact of
castration-induced AD on the uptake of metabolic PET
tracers - [18F]FDG, [11C]choline and [11C]acetate - in
PCa cells in vivo. The percentage changed uptake, based
on SUVmax and SUVmeanTH, of each tracer was evaluated
in control and AD-treated androgen-sensitive (LAPC-4)Figure 6 H&E staining of representative LAPC-4 and 22Rv1 tumour ti
magnification is ×100. AD did not affect tumour cell morphology, and nec
models. N, necrosis.and androgen-independent (22Rv1) PCa xenografts in
order to assess the impact of androgen on tracer uptake.
In the clinical setting, SUVmax is usually the preferred
value for evaluating therapy response after AD. Never-
theless, this approach quantifies only the highest tumour
uptake localised in one voxel, which is not a true
characterization of the metabolic status of the entire
tumour. For this reason, we additionally looked at the
effect of AD on the average tracer uptake in viable
tumour cells. A threshold (SUVmeanTH) was set to
exclude uptake values in necrotic tumour tissue, which
was equally present in tumours of control and castrated
animals as confirmed by histology. Moreover, since
tumour sizes were relatively large and the main objective
was to accurately quantify tumour uptake, FBP had
minor drawbacks as compared to iterative reconstructionssues grown in control and castrated animals. Original
rosis occurred equally in both experimental groups of the animal
Table 3 Prostate and seminal vesicle weight 7 days post
castration of control and androgen-deprived 22Rv1
xenograft tumours
Control Castrate p value
Prostate 1.68 ± 0.15 1.20 ± 0.07 0.0137
Seminal vesicles 2.91 ± 0.25 1.16 ± 0.04 <0.0001
Prostate and seminal vesicle weight (mg/g body weight).
Table 1 Average change of PSA secretion (ng/l/mm3
tumour)
Cell line Control Castrate p value
LAPC-4 −5.05 ± 6.19 −44.29 ± 7.71 0.0026
22Rv1 −0.58 ± 2.29 −0.88 ± 1.75 0.9185
Control versus androgen-deprived hormone-naive LAPC-4 and androgen-
independent 22Rv1 xenograft tumours.
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reconstruction [19]. Therefore, all data were reconstructed
with FBP using the same reconstruction protocol.
Regarding the image acquisition of [11C]choline and
[11C]acetate, optimal time points following the injection
of both tracers were chosen, taking into account back-
ground detection and tumoural uptake at a steady state.
In the clinical setting, [11C]choline PET imaging is pre-
ferably acquired 5 min post injection. On the other
hand, centres using [11C]acetate acquire images 30 min
post injection. A high tumour uptake was observed very
early after the injection of [11C]acetate. However, at that
time, tracer uptake was also high in the liver and
kidneys. Since background uptake of [11C]acetate dimi-
nished over time while tumour uptake remained rather
stable, a static scan 30 min after tracer injection was the
most optimal acquisition time point for tumour imaging
with [11C]acetate.
Previously, the late-term effect of AD on the uptake of
[18F]FDG and [11C]choline has been characterised in
hormone-dependent and hormone-independent PCa
xenograft models [20]. The authors demonstrated the
lower efficacy of [11C]choline PET compared to that of
[18F]FDG PET for tumour detection and therapy
response assessment in vivo after surgical castration.
Likewise, in this study, not only the trapping of [11C]
choline, but also of [11C]acetate in the xenografted
tumours was lower than that of [18F]FDG; however, the
clinical relevance of [11C]choline and [11C]acetate and
their superiority to [18F]FDG for PCa detection have
been shown. In the current study, we focussed on evalu-
ating the effect of intratumoural response to AD on PET
imaging with both these tracers as well as with [18F]FDG
[5]. Moreover, in order to minimise partial volume
effects in imaging assessment, the xenografted tumours
had to have a minimal volume of 150 mm3. However, at
this point, the proliferation rate of 22Rv1 tumours wasTable 2 Prostate and seminal vesicle weight 7 days post
castration of control and androgen-deprived LAPC-4
xenograft tumours
Control Castrate p value
Prostate 1.90 ± 0.20 1.47 ± 0.12 0.0780
Seminal vesicles 4.08 ± 0.58 1.69 ± 0.27 0.0023
Prostate and seminal vesicle weight (mg/g body weight).rather fast, wherefore long observation periods after AD
were not possible. Kukuk et al. evaluated the effect of
AD on tracer uptake 2 and 3 weeks following castration
[20], which would reflect follow-up imaging of treated
PCa in a clinical setting more precisely. However, Oyama
et al. demonstrated at an early stage androgen-regulated
effects on metabolic PET imaging in androgen-sensitive
PCa [18]. In this study, PCa xenografted tumours were
androgen-deprived for 1 week by means of diethylstilbes-
trol (DES) administration. AD significantly diminished the
uptake of [18F]FDG, but not [11C]acetate in androgen-
sensitive PCa [18]. Taken these findings into account and
the fact that androgen-induced effects on gene expression
were previously observed in preclinical models after
several days [21,22], we investigated the short-term effect
of AD, i.e. 5 days following the start of the treatment, on
metabolic PET imaging of PCa xenografted tumours.
In the current study, AD was successful in all animals,
but still, no significant change on tumour growth was
observed in castrated animals. This observation can
however be explained by the fact that AD alters gene
expression - biological/molecular changes - rather fast in
time, whereas its impact on tumour growth - morpho-
logical changes - is mostly a long-term effect. Since all
metabolic tracers involved in the study are not specific,
the effect of gene alteration on the uptake of the
molecular probes might occur later in time. Therefore,
an AD-induced inhibition of tumour proliferation, which
could have been expected in especially the androgen-
sensitive LAPC-4 model, was probably not detected in the
present study. Also, we evaluated androgen-mediated
effects by means of castration on the uptake mechanisms
of metabolic tracers. Although surgical castration signi-
ficantly reduces testicular androgen synthesis, adrenal
androgen, which provides 10% of the total androgen
production, remains present. Additionally, in tumour cells,
bioconversion of the adrenal androgen androstanediol to
dihydrotestosterone takes place of which the latter
compound causes AR transactivation [23]. Hence, surgical
castration is not equivalent to medical treatment, i.e. AR
antagonists, which reduces androgen activity locally and
in turn also limits the effect of adrenal and tumoural
androgen. Therefore, medical treatment could further
extend the effect of AD on tumour proliferation and PET
imaging.
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PCa patients, AD using bicalutamide has been shown to
significantly decrease the uptake of [11C]choline in
patients undergoing PET/CT for preoperative staging of
PCa [12]. Unlike that in patients, [11C]choline uptake
was not significantly reduced in AD-treated compared
to untreated hormone-naive xenografts (LAPC-4) in this
experiment. Because LAPC-4 cells are characterised by
the expression of the wild-type AR, they are assumed to
have a homeostatic AR signalling. A significant andro-
gen-controlled effect on choline metabolism has further
been observed in androgen-sensitive, wild-type AR-
expressing PCa cell lines [24,25]. Based on these in vitro
observations, AD-induced alterations on metabolic
imaging could have been expected in the current study.
Moreover, Jadvar et al. evaluated AD-induced effects on
[11C]choline uptake in androgen-sensitive PCa xeno-
grafted tumours using autoradiography [26]. Tumour
uptake of [11C]choline was determined 5, 10 and 20 min
post injection. Results demonstrated a significantly
higher tracer uptake in tumours of castrated animals at
only the first two time points. Compared to our study,
AD treatment was induced before androgen-sensitive
tumour cells were injected subcutaneously and thus
before solid tumours were developed. Although differ-
ences in [11C]choline uptake in these tumours were
assumed to result from androgen action, it is not
obvious whether this is completely true. In fact,
androgen-sensitive cells injected into an androgen-
depleted environment are exposed to additional stress as
compared to those cells injected into an androgen-rich
environment (control animal). Since PSA expression was
not monitored in this study and no baseline [11C]choline
uptake in the cells could be measured, it could be
questioned whether androgen-sensitive cells grown
under AD developed a truly androgen-sensitive solid
tumour after certain weeks. Hence, this would hamper
the interpretation of AD-induced effects on [11C]choline
uptake in androgen-sensitive PCa. Also, autoradiography
quantifies the tracer uptake in several tissue slices of a
certain organ, while PET offers a 3D image of a region
of interest wherefore tracer internalisation in a specific
tissue compartment of a living subject can be
approached more precisely. The experimental set-up and
imaging method used differed from those chosen in our
current study, which is most likely the reason for differ-
ent results obtained.
In patients with recurrent PCa, the development of
biochemical failure during AD is observed over time.
This stage of the disease - CRPC - is characterised by an
increasingly androgen-independent proliferation [27].
Nevertheless, androgen may still affect the expression of
genes controlled by AR signalling and the progressive
behaviour of tumours. Therefore, at this stage of thedisease AD could diminish the uptake of metabolic PET
tracers which in turn would suggest a favourable therapy
response and delay the detection of recurrences. Hence,
this study also examined androgen-induced effects on
metabolic PET imaging of the androgen-independent yet
androgen-responsive PCa xenograft model 22Rv1. AD
decreased the uptake of [18F]FDG and significantly of
[11C]choline in vivo, while tumour histology in control
and castrated animals was similar; however, [11C]acetate
PET imaging remained unaffected in both experimental
groups. These observations are in line with our previous
findings demonstrating an androgen-induced increased
uptake of [18F]FDG and [11C]choline in 22Rv1 cells [25].
Although [11C]choline PET is currently used for the de-
tection of recurrent PCa before and following AD treat-
ment of PCa, it is not yet clear whether AD should be
withdrawn on a regular basis before [11C]choline PET is
performed in androgen-resistant PCa. A recent study of
Fuccio et al. demonstrated a diminishing effect of AD on
the uptake of [11C]choline in recurrent PCa which sup-
ports the retraction of AD therapy before follow-up im-
aging in order to increase the sensitivity of [11C]choline
PET [13]. The current results support these findings,
and it is noteworthy that caution may need to be taken
for imaging recurrent PCa undergoing biochemical
failure during or following AD.
AD treatment by means of surgical castration or AR
antagonist both affect tumour viability, which can be
detected by nuclear imaging techniques. However, in
order to compare tracer internalisation in AD-treated
versus non-treated animals accurately, tracer metabolism
should remain as far as possible unaffected by AD. The
biodistribution of [18F]FDG and [11C]acetate was studied
in control and DES-treated animals [18]. In healthy rats
and tumour-bearing mice, AD did not alter tracer clear-
ance from the blood. Also, the uptake of both tracers in
background tissue compartments such as the liver,
muscle and heart was not significantly affected [18].
Therefore, the biodistribution profile of [18F]FDG and
[11C]acetate is assumed to remain unchanged after AD.
This would mean that tracer clearance should not affect
PET imaging. Regarding [18F]FDG PET, these data were
further confirmed by Jadvar et al. [28]. In a later study of
this group, [11C]choline biodistribution was studied in
castrated and non-treated tumour-bearing mice using
autoradiography. The authors concluded that AD did
not change clearance of [11C]choline [26]. In our present
study, we did not observe an altered clearance of [18F]
FDG, [11C]choline and [11C]acetate following castration,
which supports these previously obtained results.
Besides therapy, micro-environmental factors play an
important role in tumour behaviour and can affect the
evaluation of metabolic PET imaging following the treat-
ment of PCa. Necrosis and inflammation, of which the
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response assessment using PET. However, in this study,
both micro-environmental factors were equally observed
in tumour tissues of control and castrated animals.
Taking this into account and also the observation that
AD did not affect [11C]acetate uptake in androgen-
sensitive and androgen-independent xenografted tumours,
this tracer may be applicable for assessing tumour viability
after AD treatment at all stages of PCa. The potential use
of [11C]acetate PET as well as its advantage over the
currently mostly employed [11C]choline PET for the eva-
luation of advanced PCa following AD should be consi-
dered. However, because the uptake of [11C]acetate was
rather low and did not visualise proliferation as well as
that of [18F]FDG and [11C]choline, we denote the signifi-
cance of further preclinical and clinical evaluation in order
to confirm the diagnostic efficacy of [11C]acetate PET for
detecting the viability of PCa lesions before and after
therapy.
Conclusions
AD reduced the uptake of [18F]FDG and [11C]choline in
treated versus untreated androgen-independent yet
androgen-responsive PCa. Androgen did not affect
metabolic PET imaging of androgen-sensitive tumours.
Therefore, [18F]FDG-PET and especially [11C]choline-
PET, which is preferred for the detection of recurrent
PCa, could underestimate the presence of viable lesions
in patients undergoing biochemical failure early after
AD therapy. Since [11C]acetate uptake seemed to be
independent of androgen in vivo, this radiopharmaceuti-
cal may be advantageous for detecting PCa following
AD. However, it is mandatory to further investigate the
clinical significance of metabolic PET imaging with [11C]
acetate in the context of detecting tumour viability
following AD.
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